Cas:1196156-05-4 5-ethynyl-1H-pyridin-2-one manufacturer & supplier

We serve Chemical Name:5-ethynyl-1H-pyridin-2-one CAS:1196156-05-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-ethynyl-1H-pyridin-2-one

Chemical Name:5-ethynyl-1H-pyridin-2-one
CAS.NO:1196156-05-4
Synonyms:5-ethynylpyridin-2-ol
Molecular Formula:C7H5NO
Molecular Weight:119.12100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:33.12000
Exact Mass:119.03700
LogP:0.76850

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-ethynylpyridin-2-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-ethynylpyridin-2-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-ethynylpyridin-2-ol Use and application,5-ethynylpyridin-2-ol technical grade,usp/ep/jp grade.


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 5-ethynyl-1H-pyridin-2-one manufacturer Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 5-ethynyl-1H-pyridin-2-one supplier The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses. 5-ethynyl-1H-pyridin-2-one vendor The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. 5-ethynyl-1H-pyridin-2-one factory The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.